Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium Respimat in children aged 1 to 5 years with persistent asthma
NL-OMON39340Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tiotropium in asthma and persistent asthma (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Change from baseline in mean daily combined daytime asthma symptom score in the last week of the 12-week treatment period and FEV1 Peak0-3h response at week 12. Started Nov 2012; status: active, not recruiting.
02
Drugs
tiotropium
03
Conditions
asthmapersistent asthma
Beyond the preview
Go deeper on NL-OMON39340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39340.